It is indicated for patients who have contraindications or intolerance to the use of TNF inhibitors, a history of lymphoproliferative disorder, or after failure of at least one TNF inhibitor (third-line therapy).38–40,66,67. The gene discussed is TNF; the disease is lymphoproliferative syndrome.